RxDoctor Payments Data

Irshad Ahmed, MD

Internal Medicine · Colonial Heights, VANPI 1083683528

Payments from drug & device makers

$731in general payments, 2019–2025

Across 30 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shield Therapeutics Inc$150
  • AstraZeneca$127
  • Seagen Inc.$125
  • Novo Nordisk$85
  • GSK$79
  • Lilly USA, LLC$77
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$731100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Shield Therapeutics Inc6$150
AstraZeneca7$127
Seagen Inc.1$125
Novo Nordisk4$85
GSK3$79
Lilly USA, LLC4$77
Boston Scientific1$25
Amarin Pharma, Inc.1$19
Concordia Pharmaceuticals Inc.1$15
Pfizer1$14
Dexcom, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$731 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$242,172
Medicare patients
307
Services billed
4,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide78$82,666
EliquisApixaban55$46,754
JanuviaSitagliptin Phosphate35$34,304
Tresiba Flextouch U-100Insulin Degludec37$30,790
JardianceEmpagliflozin29$28,944
OzempicSemaglutide17$15,964
JanumetSitagliptin Phos/Metformin Hcl18$13,775
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$9,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,775
XareltoRivaroxaban14$7,816
Praluent PenAlirocumab13$5,823
Albuterol Sulfate HfaAlbuterol Sulfate139$5,481
Metoprolol Succinate277$3,042
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,971
Wixela InhubFluticasone Propion/Salmeterol19$2,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$77$82,66678 claims
PfizerEliquis$14$46,75455 claims
Novo NordiskOzempic$85$15,96417 claims
GSKTrelegy Ellipta$79$8,77512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Colonial Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →